Driving biotech innovation through strategic partnerships
Eralydix is a biotech innovation project developing a rapid genetic testing solution to improve the diagnosis of lactase deficiency.
We are seeking investors, biotech manufacturers, strategic partners and distributors who share our vision of making genetic diagnostics faster, more accessible and more scalable.
Why Eralydix is redefining biotech innovation in genetic diagnostics?
Eralydix tackles a major limitation in current diagnostic pathways by focusing on the genetic causes of lactase deficiency.
By combining scientific rigor, accessibility and scalability, our approach represents a new standard in biotech innovation applied to diagnostic medicine.
We are not improving existing methods — we are redefining how lactose intolerance is understood and diagnosed.
🧬 genetic approach
⚡innovation
📈 market potential
🎯 unmet need
A major global health challenge driving biotech innovation opportunities
A widespread yet underdiagnosed condition
Lactose intolerance affects a significant portion of the global population, with an estimated prevalence of around 68% worldwide.
Despite its scale, diagnosis remains inconsistent and often delayed. Patients frequently wait between 5 to 7 years before receiving an accurate diagnosis, due to non-specific symptoms and confusion with other gastrointestinal disorders.
Current diagnostic methods are indirect, sometimes invasive, and can lack reliability depending on individual conditions, leading to suboptimal patient management.
⏳ 5–7 years diagnostic delay
🌍 68% global prevalence
⚠️ Misdiagnosis common
A biotech innovation targeting the root cause
Eralydix introduces a novel approach based on rapid genetic testing, directly identifying the genetic origin of lactase deficiency.
Unlike traditional diagnostic methods that rely on indirect physiological responses, this biotech innovation provides a more precise and reproducible assessment.
This enables a shift toward personalized lactose intolerance treatment and improved clinical decision-making.
🧬 Genetic-based approach
⚡ Rapid testing solution
🎯 Direct cause identification
A scalable opportunity across global healthcare systems
With over 5 billion individuals potentially affected worldwide, lactose intolerance represents a massive and largely underserved market.
The increasing adoption of genetic testing, combined with the demand for non-invasive and scalable diagnostic tools, creates strong growth potential.
Eralydix is positioned to address multiple segments including clinical laboratories, healthcare providers and point-of-care diagnostic centers.
🌍 5.4B potential users
🏥 Clinical & healthcare markets
📈 Growing genetic testing demand
A differentiated biotech innovation with strong competitive advantages
Eralydix combines scientific robustness with operational simplicity, enabling a diagnostic solution that is both efficient and scalable.
The technology reduces dependency on laboratory infrastructure, lowers costs compared to traditional PCR-based methods, and facilitates deployment in both developed and emerging markets.
⚡ No lab infrastructure required
💸 Faster and cheaper than PCR
🌍 Access in low-income countries
📦 Scalable to large populations
Strategic partnerships to accelerate biotech innovation globally
To scale its biotech innovation, Eralydix is actively seeking strategic collaborations across the healthcare and life sciences ecosystem.
We aim to build strong partnerships to accelerate development, production and international deployment.
🧪 R&D collaboration
🏭 Manufacturing partnerships
🌍 Distribution
🤝 Co-development opportunities
🔬 Scientific collaborations
Why now is the right time to invest in this biotech innovation
Eralydix operates at the intersection of strong market demand, technological maturity and favorable regulatory dynamics.
This creates a unique timing for investors and partners to participate in the scaling of a high-potential biotech innovation.
⏱ Timing
🧠 Technology maturity
📈 Market momentum
A leadership team driving biotech innovation and global strategy
Eralydix is supported by a multidisciplinary team combining expertise in MedTech, corporate strategy, regulatory environments and international business development.
This strong foundation ensures both scientific credibility and execution capability.
Frank
Board advisory and strategy, Managing partner
BSc in radio physics /medical radiology
MBA
20 years in management position in pharma and MedTech in 4 different countries.
Key Focus on Strategy, Corporate Management, Governance
Elie
Board advisory and strategy, Managing partner
MLaw and Swiss qualified attorney at law
8 years experience in mergers & acquisitions and corporate matters, with particular focus on MedTech vertical
Key focus on investor relations, strategy and governance
Robert
Board advisory and strategy, Managing partner
He advises mid-size Canadian companies expanding into Europe on capital strategy and financial structuring.
A CPA (Canada) and CFA charter holder with 25+ years in European banking and asset management.
Let’s build the future of lactase deficiency diagnostics together
We are open to discussions with investors, industrial partners and healthcare stakeholders interested in supporting a scalable biotech innovation.
Let’s explore how we can collaborate.
Our Eralydix’s Investors & Partnership FAQ
🧬 What problem does Eralydix solve?
Eralydix addresses the lack of reliable and scalable diagnosis for lactose intolerance.
Our biotech innovation targets the genetic root cause, improving accuracy and consistency.
🚀 Why is Eralydix a strong biotech innovation?
Our solution is faster, simpler and more scalable than traditional tests.
It combines scientific precision with real-world usability.
🤝 What partnership opportunities are available?
We collaborate in R&D, manufacturing, distribution and co-development.
Our goal is to scale this biotech innovation globally.
📈 Why invest or collaborate now?
The demand for genetic testing is rapidly growing.
Eralydix is positioned at the right time, in a high-potential market.